Pfizer (NYSE:PFE) 주식

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

News

Politics

Markets

PHBBF

WUXAY

WXXWY

도널드 트럼프 대통령은 제약 회사들에게 제조를 미국으로 되돌려 놓지 않으면 관세에 직면할 것이라는 엄중한 경고를 했다고 보도되었다. 금요일(21일) 블룸버그 통신에 따르면 트럼프 대통령은 비공개 회의에서 제약사들에 임박한 관세에 대해 경고하며 해외 생산을 미국으로 서둘러 이전할 것을 촉구했다. 

트럼프, 거대 제약사에 경고 &#34;미국으로 생산 이전 안 하면 관세 부과&#34;

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Health Care Provides Index Fund

MRNA

로버트 F. 케네디 주니어가 미국 보건복지부(HHS) 장관으로 취임했다. 이는 건강보험 주식과 이를 보유한 ETF를 포함한 의료 부문에 큰 변화를 가져올 수 있다.

RFK 주니어의 美 보건복지부 장관 취임, 주목해야 할 건강보험 ETF는?

Short Ideas

Health Care

Hedge Funds

Trading Ideas

General

iShares Dow Jones US Pharmaceuticals Index Fund

켄 그리핀의 헤지펀드 시타델(Citadel)이 GSK PLC(NYSE:GSK)에 3억 5,000만 파운드(3억 9,000만 달러)의 공매도 베팅을 걸었다. 이는 영국 제약 대기업 GSK에 대한 10년래 가장 큰 베팅이라고 파이낸셜타임스가 보도했다.

켄 그리핀의 헤지펀드 시타델, 제약사 GSK에 대규모 공매도 베팅

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to $1,146,717.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $32.0 for Pfizer during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Pfizer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $20.0 to $32.0 in the last 30 days. 
<h3>Pfizer Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741377787_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$0.25</td>
<td>$0.22</td>
<td>$0.23</td>
<td>$25.00</td>
<td>$576.0K</td>
<td>35.2K</td>
<td>24.6K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.46</td>
<td>$1.42</td>
<td>$1.42</td>
<td>$26.00</td>
<td>$142.1K</td>
<td>24.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.5</td>
<td>$7.15</td>
<td>$7.3</td>
<td>$20.00</td>
<td>$109.5K</td>
<td>8.3K</td>
<td>15</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.15</td>
<td>$1.63</td>
<td>$1.8</td>
<td>$25.00</td>
<td>$90.0K</td>
<td>59.8K</td>
<td>513</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$0.24</td>
<td>$0.22</td>
<td>$0.23</td>
<td>$26.00</td>
<td>$79.3K</td>
<td>26.1K</td>
<td>7.0K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 37,526,981, the PFE's price is up by 1.73%, now at $26.7. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 54 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $33.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $33. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Pfizer's Options: A Look at What the Big Money is Thinking

<ul>
<li>CDC study follows measles outbreak amid declining vaccination rates</li>
<li>Kennedy's mixed messages on vaccines raise concerns</li>
<li>Autism rise attributed to broader screening, not vaccines</li>
</ul>
March 7 - The U.S. Centers for Disease Control and Prevention is planning a large study into potential connections between vaccines and autism, two sources familiar with the matter told Reuters, despite extensive scientific research that has disproven or failed to find evidence of such links.
It is unclear whether U.S. Health Secretary Robert F. Kennedy Jr, who has long promoted <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3PH1HA">anti-vaccine views</a>, is involved in the planned CDC study or how it would be carried out. The CDC and the Department of Health and Human Services were not immediately available for comment.
The CDC's move comes amid one of the largest <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3PN1WV">measles outbreaks</a> the U.S. has seen in the past decade, with more than 150 cases and two deaths in Texas and New Mexico. The outbreak has been fueled by declining vaccination rates in parts of the United States where parents have been falsely persuaded that such shots do more harm than good.
Kennedy, whose role includes authority over the CDC, has long sowed doubt over the safety of the combined vaccine for measles, mumps and rubella (MMR). In a cabinet meeting last week, Kennedy initially downplayed news that a school-aged child had died of measles in Texas, the first such death in a decade, calling such outbreaks ordinary and failing to mention the role of vaccination to prevent measles.
Over the weekend, Kennedy published an opinion piece on Fox News that promoted the role of vaccination, but also told parents vaccination was a personal choice and urged them to consult with their physician.
Kennedy did not immediately respond to a request for comment.
Autism diagnoses in the United States have increased significantly since 2000, intensifying public concern.
Many researchers attribute the <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3NJ17A">rise in diagnoses</a> to more widespread screening and the inclusion of a broader range of behaviors to describe the condition. But some public figures have popularized the idea that vaccines are to blame, an idea stemming from a since-debunked study from British researcher Andrew Wakefield in the late 1990s that connected a rise in autism diagnoses with widespread use of the MMR shot.
The causes of autism are unclear. No rigorous studies have found links between autism and vaccines or medications, or their components such as thimerosal or formaldehyde.
There is widespread speculation among scientists that its neurological characteristics may develop in utero, when the fetal brain is being wired. Studies have linked autism to maternal factors in pregnancy, and some research suggests a link to birth complications and timing.
President Donald Trump, in an address to Congress this week, cited the rise in autism among children. "So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you," Trump said, referring to Kennedy.
Kennedy's anti-vaccine views have drawn concern among some Republicans. During Kennedy's confirmation hearing Senator Bill Cassidy, a Louisiana Republican and physician, suggested that the nominee disavow any links between vaccines and autism.
Kennedy denied that he was anti-vaccine, but did not acknowledge that such a link had been debunked.
This week Cassidy questioned Trump's nominee to lead the National Institutes of Health, Dr. Jay Bhattacharya, over his stance on investigating a potential link between autism and childhood vaccinations.
"I don't generally believe there is a link, based on my reading of the literature," Bhattacharya said. "But we do have a sharp rise in autism rates, and I don't think any scientist really knows the cause of it. I would support a broad scientific agenda based on data to get an answer to that."

Biotech

BNTX

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

Analyst Ratings

JEPI

PAYX

CNBC Halftime Report Final Trades: Paychex, Pfizer, JPMorgan Equity Premium Income ETF

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that Quebec has become the first province to publicly reimburse APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1
ViiV Healthcare commends the Quebec government for its decision to grant timely access to APRETUDE for at-risk individuals who could benefit from PrEP. APRETUDE is now listed under the Régie de L'assurance Maladie du Québec (RAMQ). With cases of HIV continuing to rise across Canada, including in Quebec where cases have increased 37 per cent between 2019 and 2022,2 this decision will have a meaningful impact on HIV prevention efforts in the province.
APRETUDE is the first and only long-acting injectable approved in Canada to help reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents aged 12 years and older, and weighing at least 35kg.1 Findings from two real-world evidence studies (OPERA and Trio Health cohorts) showed more than 99 per cent effectiveness of APRETUDE for PrEP in nearly 1,300 individuals.3,4&nbsp;APRETUDE for PrEP has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF tablets) in reducing the risk of HIV acquisition in two clinical trials, providing more options for PrEP for Canadians.1

Global

ViiV Healthcare Announces That Quebec Has Become The First Province To Publicly Reimburse  APRETUDE For Pre-Exposure Prophylaxis To Reduce The Risk Of Sexually Acquired HIV-1 Infection In At-Risk Individuals Who Are HIV-1 Negative

Legal

German Court Rules In Favor Of Moderna In Patent Lawsuit Against BioNTech And Pfizer; German Court Rules Pfizer, BioNTech Violated Moderna's Covid-19 Vaccine Patents

In light of potential tariff threats from President Donald Trump, Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla has suggested the possibility of shifting the company&#8217;s overseas manufacturing to its U.S. facilities.
What Happened: At the TD Cowen healthcare conference, Bourla indicated that Pfizer, which already boasts an extensive U.S. manufacturing network, could relocate production to its domestic plants to avoid any potential tariffs, reported Reuters on Monday.
His remarks come as the pharmaceutical industry braces for a possible 25% tariff on imported goods. &#8220;We&nbsp;have the capabilities here (in&nbsp;the U.S.) and the manufacturing&nbsp;sites are operating in good&nbsp;capacity right now. If something&nbsp;happens, we will try to&nbsp;mitigate it by transferring from&nbsp;manufacturing sites outside to the&nbsp;manufacturing sites here,&#8221; Bourla said.
Pfizer has 10 manufacturing facilities and two distribution centers in the United States. 
SEE ALSO:<a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets"> </a><a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">Trump&#8217;s Tariffs Threaten Canada, Mexico, China — And American Wallets</a>
Why It Matters: This development follows a&nbsp;<a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">warning</a>&nbsp;from Trump to pharmaceutical companies in February. During a confidential meeting, the President urged drug companies to expedite the transfer of their overseas production to the U.S. or face the possibility of tariffs.
Among the attendees of this meeting were the CEOs of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer, along with the head of the industry's largest lobbying group. The executives aimed to convince Trump to support measures targeting middlemen blamed for increasing out-of-pocket costs and to limit a law allowing the federal government to negotiate specific drug prices.
Though the Trump administration has hinted at possible exemptions to reciprocal tariffs for certain sectors, including pharmaceuticals, a final decision is yet to be made.
While many see reshoring as a potential solution to avoid tariffs, it may not be pragmatic. Independent healthcare analyst Joshua P. Cohen wrote in Forbes, &#8220;..this takes time and is logistically complex.&#8221; He stated that generic products might call for volume purchase guarantees, and a public-private partnership may be required to boost infrastructure and regulatory compliance. &#8220;Whether the Trump administration is prepared to co-invest in a long-term strategy remains to be seen,&#8221; says Cohen.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">Reddit Co-Founder Alexis Ohanian Joins Frank McCourt&#8217;s TikTok Bid Amid Competition From MrBeast, Jesse Tinsley, And Reid Rasner</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst

Macro Economic Events

Economics

Pfizer Exec Says If There Are Significant Tariffs, Co Will Try To Move Outside Manufacturing To The U.S.

Kim Vaccarella bet her kids&#8217; college fund on her business and lost it all.
The founder of Bogg Bag dumped $60,000 into what she thought would be her big break in 2012—a massive order of her waterproof tote bags. When the shipment arrived, her heart sank. Black streaks covered every bag, rendering them unsellable.
&#8220;I went for broke and spent my kids&#8217; college money and bought a full container&#8217;s worth, and they were all bad,&#8221; Vaccarella <a href="https://www.cnbc.com/2025/02/22/highly-successful-ceos-share-best-tips-for-responding-to-setbacks.html">told CNBC Make It</a>.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a></li>
</ul>
Instead of giving up, she donated the defective bags to Hurricane Sandy victims. Those recipients started asking where they could buy more. With renewed confidence, she secured a $120,000 loan from a family friend and rebuilt.&nbsp;
Today, Bogg Bag rakes in roughly $100 million annually.
Entrepreneurs <a href="https://www.benzinga.com/startups/24/12/42618228/mark-cuban-admits-ive-gotten-beat-after-losing-20-million-on-shark-tank-startups">face setbacks all the time</a>. Some crumble. Others transform those disasters into stepping stones. CNBC Make It interviewed a few business owners who survived potentially career-ending failures before building multimillion-dollar companies.
Karen Robinovitz and Sara Schiller launched The Sloomoo Institute, a hands-on slime experience venue, in October 2019. After investing $600,000, they sold $1 million in tickets their first week. Then COVID hit.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Five months after opening, they laid off 90 part-time workers, keeping just their co-CEOs, a bookkeeper, and their slime expert.
Rather than folding, they hustled. They switched to online slime sales. They created virtual slime-making camps for kids stuck at home. They ran corporate workshops for companies like Google and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) until they could fully reopen in 2021.
It paid off. Now, their five U.S. locations bring in about $4.3 million monthly from in-person tickets.
&#8220;We want people to know that you can choose to try, get out there and do something that&#8217;s never been done before,&#8221; Schiller told CNBC. &#8220;After what we&#8217;ve both been through, what are we going to be afraid of now?&#8221;
See Also: <a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a>
Sometimes the biggest obstacle is the reflection in the mirror. Shizu Okusa learned the lesson after watching her first company, Jrink, collapse despite seven years in business.
The cold-pressed juice company couldn&#8217;t overcome high costs and rapid spoilage. But Okusa admits her management style was the deeper problem.
&#8220;One of the key lessons was getting out of my own way,&#8221; Okusa told CNBC. She treated Jrink like her baby, refusing to trust her team with critical decisions. &#8220;In terms of allowing and hiring people that were much better than I was in certain areas of business. Now, I just move aside. I have my strengths and give my weaknesses away.&#8221;
These entrepreneurs&#8217; stories reveal common threads—an unwavering belief in your concept, willingness to adapt when plans implode, and knowing when to get out of your own way.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>

From Losing $60K To Running a $100M Business: CEOs Share Their Biggest Lessons

On Tuesday, LAVA Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) initiated a process to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43936254/lava-announces-evaluation-of-strategic-options" rel="noreferrer noopener">review strategic options</a>.
The company implemented cost curtailment, including a workforce reduction, and has retained a financial advisor to support the strategic evaluation process.
LAVA Therapeutics will continue to enroll in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42912100/lava-doses-first-patient-in-phase-1-lava-1266-study-in-hematological-cancers" rel="noreferrer noopener">Phase 1 clinical study</a> evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and support its partnerships with Pfizer Inc and Johnson and Johnson.
In 2020, Lava Therapeutics <a target="_blank" href="https://www.lavatherapeutics.com/press-release/lava-therapeutics-announces-collaboration-with-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics/" rel="noreferrer noopener">announced</a> a research and license agreement with Janssen Biotech, Inc. to discover and develop novel bispecific antibodies to gamma-delta T cells for cancer.
In March 2024, LAVA Therapeutics announced that Pfizer achieved a development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment <a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37478540/lava-announces-clinical-development-milestone-achieved-by-pfizer-for-pf-08046052-formerly-sgn-egfr" rel="noreferrer noopener">of $7 million to LAVA</a>.
LAVA granted Seagen (acquired by Pfizer in December 2023) a worldwide exclusive license to PF-08046052 <a target="_blank" href="https://www.benzinga.com/pressreleases/22/09/b29006441/seagen-and-lava-therapeutics-announce-exclusive-worldwide-license-agreement-to-advance-lava-1223-a" rel="noreferrer noopener">in September 2022</a>.
As of December 31, 2024, the company&#8217;s cash balance was $76.6 million.
In December, the company&#8217;s said cash runway extended into 2027, based on a cash balance of $78.9 million as of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42410106/lava-reports-third-quarter-2024-financial-results-and-announces-pipeline-reprioritization-and-cash" rel="noreferrer noopener">September 30, 2024</a>.
On Thursday, HC Wainwright downgraded LAVA Therapeutics to Neutral from Buy with a <a target="_blank" href="https://www.benzinga.com/quote/LVTX/analyst-ratings" rel="noreferrer noopener">price target of $1.50</a>, citing pipeline overhang despite substantial cash reserve.
Analyst Arthur He writes, &#8220;While we are not surprised by management&#8217;s decision given the challenging market conditions, it does generate uncertainties regarding the company&#8217;s only clinical asset, LAVA-1266 for hematological malignancies, as it depends on the outcome of the strategic review.&#8221;
HC Wainwright expects three possible outcomes for LAVA Therapeutics in the next year:
<ul>
<li>Acquiring one or more proven drug candidates</li>
<li>Merging with another company through a reverse merger</li>
<li>Continuing its current operations while waiting for initial clinical results from LAVA-1266</li>
</ul>
LAVA-1266 could be sidelined in favor of new projects in the first two scenarios. Given this uncertainty, HC Wainwright believes it is best to wait for more clarity.
Price Action: LVTX stock is down 0.78% at $1.28 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/44046417/ani-pharmaceuticals-expects-strong-start-to-2025-on-back-of-cortrophin-gel-and-generics-lifts-annual-forecast" target="_blank" rel="noreferrer noopener">ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Downgrades

Price Target

LVTX

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

AMGN

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-names-former-fda-director-patrizia-cavazzoni-chief-medical-officer-2025-02-24/#:~:text=Feb%2024%20(Reuters)%20%2D%20Pfizer,other%20medical%20functions%20at%20Pfizer

Management

'Pfizer Names Former FDA Director Patrizia Cavazzoni As Chief Medical Officer' - Reuters News

<a href="https://www.benzinga.com/personal-finance/25/01/42992135/billionaire-bill-gates-was-asked-whats-left-on-his-bucket-list-he-reveals-theres-only-one-thing-dont-die">Bill Gates</a> has been warning about pandemics for nearly a decade, but his biggest fear isn't just another outbreak—it's that the world isn't learning from past mistakes.
Even after COVID-19, which shut down economies and killed millions, Gates says we're still not prepared for the next global health crisis.
In March 2023, he <a href="https://www.nytimes.com/2023/03/19/opinion/bill-gates-pandemic-preparedness-covid.html">wrote an opinion piece</a> for The New York Times, saying the world is once again making the same costly mistakes. "We can't afford to get caught flat-footed again," he wrote.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
To make his point, he compared pandemic preparedness to fighting a fire:
"Imagine there's a small fire in your kitchen… We need to prepare to fight disease outbreaks just as we prepare to fight fires."
Back in 2015, he gave a <a href="https://www.ted.com/talks/bill_gates_the_next_outbreak_we_re_not_ready">TED Talk</a> warning that the world was "not ready" for a major outbreak. Five years later, COVID-19 proved him right. Now, with the threat of another pandemic looming, he believes not enough has changed.
<h2 class="wp-block-heading">A 10-15% Chance of Another Pandemic—And the World Isn't Ready</h2>
In an interview with the <a href="https://www.wsj.com/tech/bill-gates-on-his-meeting-with-trump-musks-doge-his-childhood-d4a02114">The Wall Street Journal</a> in January, Gates estimated there's a 10% to 15% chance of a naturally occurring pandemic within the next four years. The scary part? Despite COVID-19's devastating impact, he says the world remains "absolutely not" ready.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
His biggest concern is that leaders aren't investing in prevention—even though it's far cheaper than dealing with a full-blown crisis. He's been pushing for several key initiatives to close this gap:
<ul>
<li>A global "fire department" for pandemics – A team of rapid-response health experts ready to contain outbreaks before they spread.</li>
<li>Stronger global surveillance – Using sewage testing, airport air monitoring, and AI-driven detection to catch diseases early.</li>
<li>Public health infrastructure upgrades – Ensuring hospitals, labs, and emergency responders can act fast when needed.</li>
<li>Government &amp; private-sector partnerships – Urging companies like Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) to work alongside world health leaders to develop faster vaccines and treatments.</li>
</ul>
<h2 class="wp-block-heading">"We Need a Fire Department for Pandemics"</h2>
One initiative Gates is optimistic about is the Global Health Emergency Corps, a World Health Organization-led program designed to train and coordinate health leaders worldwide.
Gates writes, "the next ‌pandemic could emerge anywhere, and so the Emergency Corps must have expertise from every corner of the globe."
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The idea is simple: just as firefighters run drills and prepare for emergencies, this corps would conduct outbreak simulations so countries know exactly how to respond when a new virus emerges.
<a href="https://www.benzinga.com/markets/24/10/41457050/bill-gates-once-said-he-was-so-jealous-of-apples-steve-jobs-and-labeled-him-a-genius-and-wizard-no-o">Gates isn't convinced</a> that governments are moving fast enough. In his New York Times op-ed, he warned: "The world hasn't done as much to get ready for the next pandemic as I'd hoped. But it's not too late to stop history from repeating itself."
<h2 class="wp-block-heading">The Cost of Ignoring Gates' Warnings</h2>
<a href="https://www.benzinga.com/personal-finance/25/02/43562104/bill-gates-was-the-richest-man-in-the-world-for-a-record-18-years-he-says-money-brings-freedom-but-beyond-that-its-the-same-hamburger">Gates has spent years</a> trying to shift the conversation from reaction to prevention, arguing that proactive investments in pandemic preparedness are a bargain compared to the trillions lost when a crisis hits.
Yet despite the economic and human toll, global health funding remains shockingly low. Gates emphasizes the time to prepare for the next pandemic isn't when it starts—it's right now.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

Bill Gates Says 'Next Pandemic Can Emerge Anywhere' And The World Isn't Prepared: 'We Can't Afford To Get Caught Flat-Footed Again'

&nbsp;
 -Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) today announced a clinical trial collaboration with Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
&nbsp;
"Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted Bob Duggan and Dr. Maky Zanganeh, Summit's Co-CEOs. "As we seek to accelerate the development of our potentially transformative ivonescimab across non-small cell lung cancer and other solid tumor settings, this collaboration will allow us to quickly advance beyond our promising late-stage development plan to evaluate ivonescimab in combination with some of the most innovative ADCs from Pfizer."
The goal of the collaboration is to evaluate ivonescimab, in combination with several unique Pfizer ADCs across multiple solid tumor settings to accelerate the advancement of potentially landscape-changing combinations, which seek to improve the standards of care for patients facing serious unmet needs. Each study intends to evaluate ivonescimab plus one of Pfizer's vedotin ADCs in individual, distinct solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.

SMMT

Summit Therapeutics and Pfizer Partner to Advance Cancer Treatment With Novel Antibody Combinations

The companies will evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
Under the terms of the agreement, Summit will provide ivonescimab for use in the proposed studies, and Pfizer will be responsible for conducting the operations of the studies. The studies will be overseen by both Summit and Pfizer. Both parties retain their respective rights to their products. The studies combining ivonescimab with Pfizer's vedotin ADCs are planned to begin in the middle of this year. Further details on the clinical trials will be announced at a later date.

Summit Therapeutics Enters Clinical Trial Collaboration With Pfizer, No Financial Terms Disclosed

Robert F. Kennedy Jr.&#8216;s appointment as U.S. Secretary of Health and Human Services has sparked concerns over funding for the National Institutes of Health. Analysts warn that potential cuts to this funding could lead to increased &#8220;uncertainty&#8221; in the healthcare sector, potentially impacting healthcare stocks.
What Happened: The NIH grants are &#8220;very important&#8221; sources of funding for a lot of labs out there, said Kyle Mikson, managing director and senior research analyst in <a href="https://www.buzzsprout.com/2414939/episodes/16662667">conversation</a> with Michael Graham, senior managing director and head of U.S. equity research internet analyst at Canaccord Genuity. 
Talking about RFK Jr.&#8217;s appointment Mikson said &#8220;He&#8217;s got some opposition to vaccines, to infectious disease research.&#8221; Highlighting the possible funding cuts along with caps on grants, Mikson added, "Things like that are causing uncertainty, causing, you know, stocks to decline."
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html">reports</a>. Through his nonprofit, Children's Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
The Donald Trump-led <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">administration</a> is trying to set caps at around 15% and 10% for some labs which is delayed due to broad opposition by many states. While this is detrimental to some NIH-funded labs, others have stated that they can function without indirect cost funding or support.
While, NIH awarded about $2.5 billion in grants in the first six weeks of 2024, this year, that number has plummeted to $1.4 billion.
See Also: <a href="https://www.benzinga.com/25/02/43906366/warren-buffetts-berkshire-boosts-bets-on-five-japanese-companies-admiration-has-consistently-grown-says-oracle-of-omaha-in-letter-to-shareholders">Warren Buffett&#8217;s Berkshire Boosts Bets On 5 Japanese Companies: Oracle Of Omaha Says Admiration &#8216;Has Consistently Grown&#8217;</a>
Why It Matters: While there isn't going to be a blanket impact of these caps on all healthcare firms, Mikson explains that companies that are academically focused are more likely to be impacted as compared to the ones with a mixed revenue base.
However, when considering investment opportunities, especially for growth-oriented companies with research-driven businesses, the impact is particularly important, Mikson explained.
According to the <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">13F SEC filings</a> during the fourth quarter, healthcare sectors experienced a sharp decline in investments, with allocations dropping by 1.4%. Adam Turnquist, the chief technical strategist at LPL Financial said that "The nomination of the so-called anti-vaccine Health Secretary, Robert F. Kennedy, Jr., and the potential for reduced Affordable Care Act subsidies," was also a potential trigger.
Kennedy&#8217;s appointment comes as healthcare costs rise and <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says">bird flu spreads</a>, raising pandemic concerns. A longtime vaccine skeptic, his stance could impact pharmaceutical companies like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), especially as he has questioned the safety and efficacy of bird flu vaccines.
Here is a list of healthcare sector-linked exchange-traded funds, that investors could consider while trying to gain exposure to the sector.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>6.41%</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Vanguard Health Care ETF VHT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHT#NYSE">VHT</a>)</td>
<td>5.79%</td>
<td>-0.19%</td>
</tr>
<tr>
<td>iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>)</td>
<td>4.51%</td>
<td>-0.18%</td>
</tr>
<tr>
<td>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)</td>
<td>0.19%</td>
<td>-5.79%</td>
</tr>
<tr>
<td>iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)</td>
<td>10.36%</td>
<td>12.22%</td>
</tr>
<tr>
<td>iShares Global Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXJ#NYSE">IXJ</a>)</td>
<td>6.67%</td>
<td>-0.57%</td>
</tr>
<tr>
<td>iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>)</td>
<td>5.52%</td>
<td>-0.26%</td>
</tr>
<tr>
<td>Fidelity MSCI Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHLC#NYSE">FHLC</a>)</td>
<td>5.90%</td>
<td>-0.27%</td>
</tr>
<tr>
<td>ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td>10.14%</td>
<td>-14.26%</td>
</tr>
<tr>
<td>First Trust NYSE Arca Biotechnology Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBT#NYSE">FBT</a>)</td>
<td>6.72%</td>
<td>16.97%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty</a></li>
</ul>
Image Via Shutterstock

Government

Market Summary

Regulations

ETFs

ARKG

First Trust NYSE Arca Biotechnology Index Fund

FHLC

iShares Dow Jones US Medical Devices Index Fund

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs.
What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging them to hasten the transfer of their overseas production to the U.S., reported <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">Bloomberg</a> on Friday.
On Thursday, the CEO of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) David Ricks, CEO of Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Robert Davis, CEO OF Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, and Stephen Ubl, head of the industry&#8217;s largest lobbying group met Trump at the White House. The executives aimed to persuade Trump to back efforts to limit a law permitting the federal government to negotiate specific drug prices and to support measures targeting middlemen whom the industry holds responsible for increasing out-of-pocket costs.
As per the Bloomberg report, Trump did not assure to advocate with Congress to alleviate a drug pricing program established under former President Joe Biden&#8216;s tenure, a relief that the pharmaceutical sector has been seeking.
Medicare officials confirmed on Friday that the next phase of the drug pricing negotiation program&nbsp;is due and would include Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster weight loss drugs, Ozempic and Wegovy. 
Meanwhile, Trump stated that Health and Human Services Secretary Robert F. Kennedy Jr. and his nominee for leading Medicare and Medicaid, Mehmet Oz, are working to reduce drug prices.
SEE ALSO: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43904842/dominos-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Domino&#8217;s Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Last week, Trump proposed to <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">impose a 25% tariff </a>on pharmaceuticals imported to the U.S. This latest move by Trump is not surprising given his previous confrontations with the pharmaceutical industry. During his first term, he even accused them at one point of &#8220;getting away with murder&#8221; with their drug pricing. 
ING Bank estimates that the U.S. imported nearly 36% of the drugs in 2024 with Ireland, Germany, and Switzerland being the top importers. Meanwhile, data from the Atlantic Council shows that U.S. imports of Chinese drugs surged 485% between 2020-2022.&nbsp;Following Trump&#8217;s latest warning to drugmakers to shift production in the U.S., Chinese biotech shares have taken a hit during their Asian trading session today. Shares of WuXi Biologics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>) and Pharmaron Beijing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) witnessed significant declines. 
That being said, ING asserted that Trump&#8217;s call for expanding U.S. pharmaceutical manufacturing is justified, as a report from the Biden administration had indicated that capacity restrictions were the cause of drug shortages. However, a 2022 report by Washington University&nbsp;revealed that the capacity expansion would take between two to three years. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43901182/bernie-sanders-warns-if-elon-musk-can-fire-hundreds-of-thousands-of-federal-employees-imagine-what-hell-do-to-private-sector-workers">Bernie Sanders Warns: If Elon Musk Can Fire Hundreds Of Thousands Of Federal Employees, Imagine What He&#8217;ll Do To Private Sector Workers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

On Friday, Exelixis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) authorized repurchasing up to an additional $500 million of the company&#8217;s common stock before <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43868849/exelixis-announces-a-newly-authorized-500-million-stock-repurchase-program" rel="noreferrer noopener">December 31, 2025</a>.
Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.
As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.
Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 43 cents</a>. The cancer-focused company reported sales of $566.75 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640071/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-corporate-up" rel="noreferrer noopener">consensus of $563.42 million</a>.
Exelixis reaffirmed its 2025 sales guidance of $2.15 billion-$2.25 billion versus consensus of $2.24 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a>
Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx&nbsp;(cabozantinib) in combination with Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib regardless of the IMDC risk group.
In January, Exelixis announced that its supplemental New Drug Application (sNDA) for cabozantinib for adults with previously treated advanced pancreatic neuroendocrine and extra-pancreatic tumors will no longer be discussed at the FDA&#8217;s Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions" target="_blank" rel="noreferrer noopener">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>

Buybacks

Movers

EXEL

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

WIIM

Shares of vaccine makers are trading higher after the Daily Mail reported a new coronavirus was discovered in China.

<a href="https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html">https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html</a>
&nbsp;

NVAX

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

According to multiple media reports on Thursday, Pfizer&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.
In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
In a statement to&nbsp;Nikkei Asia, Pfizer <a target="_blank" href="https://asia.nikkei.com/Business/Pharmaceuticals/Pfizer-halts-work-on-hemophilia-gene-therapy" rel="noreferrer noopener">said</a> the decision was due to "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.&#8221;
The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.
In December 2024, Pfizer walked away&nbsp;from its hemophilia A co-development pact with Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) giroctocogene fitelparvovec, an investigational gene <a target="_blank" href="https://www.benzinga.com/24/12/42740738/sangamo-therapeutics-stock-plunges-as-pfizer-terminates-hemophilia-gene-therapy-pact" rel="noreferrer noopener">therapy product candidate</a>.
According to a Reuters report, Pfizer will continue to invest resources in Hympavzi (marstacimab-hncq), which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">auto-injector pen</a>.
Earlier this month, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">with and without inhibitors</a>.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta&nbsp;(voxelotor) for sickle cell disease (SCD) in all markets&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41035514/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worl" rel="noreferrer noopener">where it is approved</a>.
Pfizer's decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048780/pfizer-voluntarily-withdraws-sickle-cell-disease-treatment-oxbryta-from-global-market-due-to-pain" rel="noreferrer noopener">cell patient population</a>.
Price Action: PFE stock is up 0.87% at $26.13 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43885302/apple-expands-apple-tv-to-android-eyes-subscription-growth-and-ecosystem-expansion-analyst-says" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>

Large Cap

SGMO

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Press Releases

GeminiBio Appoints Mike Stella to Board

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Quebec becomes first province to publicly reimburse APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP)

AKYA

CMBM

CSCO

DOMO

FTSW

ICLR

ILMN

PRAH

QTRX

SFSF

YDLE

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

뉴스

파트너 / 기고자

벤징가 글로벌